1. 1169PRORγ agonist LYC-55716 in combination with pembrolizumab to treat metastatic non-small cell lung cancer: An open-label, multicenter phase Ib trial. (23rd October 2018) Authors: Camidge, D R; Gadgeel, S M; Wilkins, H J; Weems, G; Santana-Davila, R; Johnson, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SO-002Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF). (2nd July 2019) Authors: Chau, I; Bendell, J; Soriano, A; Arkenau, H; Cultrera, J; Santana-Davila, R; Calvo, E; Tourneau, C Le; Zender, L; Mi, G; Schelman, W; Ferry, D; Herbst, R; Fuchs, C Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗